Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2022-09-15 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER AND REQUEST FORM
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 16 September 2022 from Uni-Bio Science Group Limited informing non-registered shareholders about the publication of the 2022 interim report for the six months ended 30 June 2022 on the company's website. It includes instructions on how to request a printed copy of the interim report and future corporate communications. The document does not contain the interim report itself or any substantive financial data, but rather serves as a notice of the report's availability and instructions for obtaining it. The document length is 4689 characters, which is relatively short and consistent with a notification rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report publication, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2022-09-15 English
Interim Report 2022
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial data for the six months ended 30 June 2022, including condensed consolidated statements of profit or loss, financial position, cash flows, and changes in equity. It also includes management discussion and analysis, key financial highlights, business review, and segment financial figures. The presence of unaudited condensed consolidated interim results and detailed financial statements for a half-year period indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Uni-Bio Science Group Limited, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital movements and share option schemes rather than financial performance or earnings. It is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory filing reporting share capital and share option movements for a specific month (August 2022). The document is lengthy (over 10,000 characters) and contains substantive data, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance documents that do not fit other specific categories.
2022-09-02 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022' and contains detailed financial data, including revenue, profit, segment results, and management discussion and analysis for the six-month period ending June 30, 2022. It includes unaudited condensed consolidated interim results and substantive financial figures, as well as business and market reviews. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2022
2022-08-29 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from Uni-Bio Science Group Limited stating the date of a board meeting scheduled to approve and publish the interim financial results for the six months ended 30 June 2022. The document does not contain the actual interim financial results or substantive financial data, but rather announces the upcoming board meeting and the intention to approve and publish the interim results. The document length is short (1641 characters) and it serves as a notice rather than the report itself. According to the 'MENU VS MEAL' rule, this type of document is classified as a Report Publication Announcement (RPA) rather than an Interim Report (IR).
2022-08-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return on movements in securities for Uni-Bio Science Group Limited, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and relates to the month ended 31 July 2022. The content focuses on share capital changes, share options, and compliance confirmations rather than financial performance, earnings, or management commentary. It is a regulatory submission about share capital and securities movements rather than a financial report or announcement of voting results. This type of document fits best under the category of Share Issue/Capital Change (SHA), as it details changes and movements in share capital and share options.
2022-08-01 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.